Simulations Plus, Inc. · NASDAQ:SLP
Simulations Plus — FY2022 Earnings Presentation
20 slides from Simulations Plus's earnings presentation, Oct 26, 2022
Slide 1: Earnings Call - Q4 - FY22
Earnings Call - Q4 - FY22 October 26, 2022 1 1 | NASDAQ: SLP
Slide 2: Safe Harbor Statement
Safe Harbor Statement With the exception of historical information, the matters discussed in this presentation are forward- looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing,
Slide 3: Full Year Highlights
Full Year Highlights 16% 28% 24% 22% Revenue Growth Diluted EPS Adj. EBITDA Services Backlog Growth Growth Growth Achievements • Continued scientific leadership in biosimulation market with expanding industry and regulatory partnerships • Accelerating revenue growth and improved profitability • Leve
Slide 4: Fourth Quarter & Full Year Software Highlights
Fourth Quarter & Full Year Software Highlights General • Renewal rate in line with historical levels but impacted by delayed client process and forex • University+ program has 245 individual licenses across 53 countries -8% GastroPlus® +15% • 6 new commercial customers in Q4 Q4 Revenue • 7 upsells i
Slide 5: Fourth Quarter & Full Year Services Highlights
Fourth Quarter & Full Year Services Highlights General • 22% increase in backlog compared to prior year • Dynamic market for scientific talent +3% PKPD +4% Q4 Revenue • Higher than usual seasonality for summer months • Rising utilization and project pricing yields FY Revenue Growth Growth +29% QSP/Q
Slide 6: FY23 Outlook
FY23 Outlook FY23 Guidance: Commentary: 10% to 15% • Software business continues to deliver Total Revenue Growth with strong momentum. • Services business improving with $59.3M to $62.0M significant improvement in backlog Total Revenue entering FY23 60% to 65% • Consistent annual renewal rates with
Slide 7: Financial Results
Financial Results 7 | NASDAQ: SLP
Slide 8: Revenue - Q4
Q4 Revenue (in millions) Revenue - Q4 (in millions) 4Q22 Mix 4Q21 Mix +19% +10% +30% Total Revenue Software Revenue Services Revenue 8 | NASDAQ: SLP
Slide 9: Revenue - Fiscal Year
Q4 Revenue (in millions) Revenue - Fiscal Year (in millions) FY22 Mix FY21 Mix +16% +18% +13% Total Revenue Software Revenue Services Revenue 9 | NASDAQ: SLP
Slide 10: Gross Margin Trends - Q4
Gross Margin Trends - Q4 10 | NASDAQ: SLP
Slide 11: Gross Margin Trends - Fiscal Year
Gross Margin Trends - Fiscal Year 11 | NASDAQ: SLP
Slide 12: Software Revenue by Product
Software Revenue by Product Q4 FY22 FY22 Other Other Software Product as % of Software Revenue 12 | NASDAQ: SLP
Slide 13: Software Performance Metrics - Q4
Software Performance Metrics - Q4 Commercial Customers Avg. Revenue per Customer Renewal Rates (in thousands) 13 | NASDAQ: SLP
Slide 14: Software Performance Metrics - Fiscal Year
Software Performance Metrics - Fiscal Year Commercial Customers Avg. Revenue per Customer Renewal Rates (in thousands) University+ Customers: 245 in 53 countries 14 | NASDAQ: SLP
Slide 15: Service Revenue by Type
Service Revenue by Type 4Q22 FY22 PKPD PKPD QSP/QST QSP/QST PBPK PBPK Other Other Services as % of Service Revenue 15 | NASDAQ: SLP
Slide 16: Services Performance Metrics
Services Performance Metrics Total Projects Backlog 16 | NASDAQ: SLP
Slide 17: Income Statement Summary - Q4
Income Statement Summary - Q4 (in millions, except Diluted EPS) 4Q22 % of Rev 4Q21 % of Rev Revenue $11.7 100% $9.8 100% Revenue growth 19% 3% Gross profit 9.1 77% 7.1 72% R&D 0.8 7% 1.3 13% SG&A 7.6 65% 5.6 57% Total operating exp 8.4 71% 6.9 70% Income from operations 0.7 6% 0.2 2% Income before i
Slide 18: Income Statement Summary - Fiscal Year
Income Statement Summary - Fiscal Year (in millions, except Diluted EPS) FY22 % of Rev FY21 % of Rev Revenue $53.9 100% $46.5 100% Revenue growth 16% 12% Gross profit 43.1 80% 35.9 77% R&D 3.2 6% 4.0 9% SG&A 25.0 46% 20.6 44% Total operating exp 28.2 52% 24.6 53% Income from operations 14.9 28% 11.3
Slide 19: Balance Sheet Summary
Balance Sheet Summary (in millions) August 31, 2022 August 31, 2021 Cash and short-term investments $128.2 $123.6 Total current assets 146.8 139.3 Total assets $188.4 $180.0 Current liabilities 7.7 11.6 Long-term liabilities 2.4 2.6 Total liabilities 10.1 14.2 Shareholders’ equity 178.2 165.8 Total
Slide 20: Conclusion
Conclusion CONTINUED LEADERSHIP POSITION IN BIOSIMULATION MARKET • Delivering on our commitment to scientific leadership ◦ Internal R&D investment ◦ Expanding industry and regulatory partnerships • Enhancing our client facing capabilities ◦ Growth and maturity of business development team ◦ Focus on